What changed: Gastric & gastro-oesophageal junction cancer
Every dated change on the records linked to Gastric & gastro-oesophageal junction cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
August 2026 · 1
2026 · 3
- 2026Trial resultCLARITY-Gastric 01CLARITY-Gastric 01 reported
Co-primary endpoints including OS met (July 2026); numbers pending.
- 2026Trial resultHERIZON-GEA-01HERIZON-GEA-01 reported
PFS 12.
- 2026MilestoneHERIZON-GEA-01HERIZON-GEA-01: zanidatamab beats trastuzumab; CLARITY-Gastric 01: first CLDN18.2 ADC with OS benefit
A milestone in how this cancer is treated.
November 2025 · 1
September 2025 · 1
2025 · 6
- 2025ApprovalSatricabtagene autoleucelSatricabtagene autoleucel approved in China
CLDN18.2+ advanced gastric/GEJ adenocarcinoma, previously treated
- 2025Trial resultDESTINY-Gastric04DESTINY-Gastric04 reported
OS 14.
- 2025Trial resultFORTITUDE-101FORTITUDE-101 reported
Interim OS 17.
- 2025Trial resultMATTERHORNMATTERHORN reported
EFS HR 0.
- 2025MilestoneMATTERHORNMATTERHORN: perioperative durvalumab approved; DESTINY-Gastric04 phase 3; satri-cel CAR-T approved in China; FORTITUDE-101 mixed; CheckMate 649 five-year data
A milestone in how this cancer is treated.
- 2025MilestoneSatricabtagene autoleucelSatri-cel CAR-T approved in China
A milestone in how this cancer is treated.
December 2024 · 1
2024 · 7
- 2024ApprovalCadonilimabCadonilimab approved in China
First-line persistent/recurrent/metastatic cervical cancer with chemotherapy ± bevacizumab; first-line gastric cancer with chemotherapy
- 2024ApprovalTislelizumabTislelizumab approved in US
Second-line ESCC after chemotherapy; first-line HER2-negative gastric/GEJ with chemotherapy (PD-L1 ≥1)
- 2024ApprovalZolbetuximabZolbetuximab approved in EU
1L CLDN18.2+ HER2- gastric/GEJ; 19 Sep 2024
- 2024ApprovalZolbetuximabZolbetuximab approved in Japan
CLDN18.2+ HER2- gastric cancer (first approval, March 2024)
- 2024ApprovalZolbetuximabZolbetuximab approved in US
First-line CLDN18.2+ (≥75%), HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with fluoropyrimidine/platinum chemotherapy
- 2024MilestoneZolbetuximabZolbetuximab approved (Japan March, US October); zanidatamab approved in biliary cancer
A milestone in how this cancer is treated.
- 2024MilestoneGastric & gastro-oesophageal junction cancerZolbetuximab: first CLDN18.2 drug
A milestone in how this cancer is treated.
2023 · 6
- 2023ApprovalSintilimabSintilimab approved in China
First-line gastric or gastro-oesophageal junction adenocarcinoma with chemotherapy (ORIENT-16)
- 2023Trial resultKEYNOTE-859KEYNOTE-859 reported
OS HR 0.
- 2023Trial resultLow-dose olanzapine for cancer anorexia (Tata Memorial)Low-dose olanzapine for cancer anorexia (Tata Memorial) reported
Weight gain over 5%: 60% vs 9%; appetite improvement 43% vs 13%.
- 2023Trial resultORIENT-16ORIENT-16 reported
OS 15.
- 2023Trial resultSPOTLIGHT & GLOWSPOTLIGHT & GLOW reported
SPOTLIGHT OS 18.
- 2023MilestoneSPOTLIGHT & GLOWSPOTLIGHT and GLOW: Claudin 18.2 validated; KEYNOTE-859
A milestone in how this cancer is treated.
January 2022 · 1
June 2021 · 1
January 2021 · 1
2021 · 4
- 2021ApprovalDisitamab vedotinDisitamab vedotin approved in China
HER2+ gastric cancer; HER2-expressing urothelial cancer
- 2021Trial resultCheckMate 577CheckMate 577 reported
DFS 22.
- 2021MilestoneCheckMate 649CheckMate 649: nivolumab + chemotherapy first line; KEYNOTE-811 adds pembrolizumab to trastuzumab; T-DXd approved (DESTINY-Gastric01)
A milestone in how this cancer is treated.
- 2021MilestoneNivolumabNivolumab + chemotherapy first line
A milestone in how this cancer is treated.
2020 · 1
2019 · 3
- 2019ApprovalTislelizumabTislelizumab approved in China
Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal
- 2019ApprovalTrifluridine/tipiracilTrifluridine/tipiracil approved in US
Refractory metastatic gastric/GEJ cancer (TAGS)
- 2019MilestoneFLOT (5-FU, leucovorin, oxaliplatin, docetaxel)FLOT4: docetaxel quadruplet becomes perioperative standard; trifluridine/tipiracil third line (TAGS)
A milestone in how this cancer is treated.
2017 · 2
2014 · 4
- 2014ApprovalRamucirumabRamucirumab approved in US
Gastric cancer; NSCLC
- 2014ApprovalRivoceranib (apatinib)Rivoceranib (apatinib) approved in China
Advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines
- 2014Trial resultRAINBOWRAINBOW reported
OS 9.
- 2014MilestoneRAINBOWTCGA molecular classification; RAINBOW establishes ramucirumab + paclitaxel
A milestone in how this cancer is treated.
2012 · 1
2011 · 1
October 2010 · 1
2010 · 5
- 2010ApprovalHER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH) approved in US
HER2 testing extended to gastric and GEJ adenocarcinoma with trastuzumab (ToGA)
- 2010ApprovalTrastuzumabTrastuzumab approved in US
HER2+ gastric cancer
- 2010Trial resultToGAToGA reported
OS 13.
- 2010MilestoneTrastuzumabToGA: trastuzumab in HER2+ gastric cancer
A milestone in how this cancer is treated.
- 2010MilestoneToGAToGA: trastuzumab, the first targeted therapy in gastric cancer
A milestone in how this cancer is treated.